
Biofrontera overcomes combination product hurdles to enter US market
German biopharmaceutical company Biofrontera has finally cracked the US market with its combination product, gaining access to 58 million Americans with actinic keratosis.
German biopharmaceutical company Biofrontera has finally cracked the US market with its combination product, gaining access to 58 million Americans with actinic keratosis.